{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T10:17:15Z","timestamp":1756462635297,"version":"3.40.5"},"reference-count":20,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2019,2,14]],"date-time":"2019-02-14T00:00:00Z","timestamp":1550102400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J of Rheum Dis"],"published-print":{"date-parts":[[2019,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objectives<\/jats:title><jats:p>To evaluate the transition from reference infliximab Remicade to biosimilar Remsima in patients with rheumatoid arthritis (RA) or psoriatic arthritis (PsA).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients were informed through a letter about the transition to a biosimilar and were subsequently contacted for possible additional questions and whether they agreed upon the transition. Once agreed, Remsima was administered at the same dosage and interval as previous treatment with Remicade. Data on the transition were analyzed in January 2018. The primary outcome was the percentage of patients continuing treatment with Remsima and secondary outcome was the change in disease activity measured with the Disease Activity Score in 28 joints using erythrocyte sedimentation rate (DAS28\u2010ESR). In addition, the reasons for discontinuation with infliximab or restarting Remicade were recorded.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In total 47 patients were approached, 45 patients switched from Remicade to Remsima, two patients disagreed upon transition and continued Remicade. At the end of the follow\u2010up period of 2 years, 39 patients (87%) continued with Remsima, three patients (7%) restarted Remicade due to inefficacy according to the patient (this was not objectified by the rheumatologist) 2 (4%) patients switched to another biological due to lack of effect and in one patient (2%) infliximab was stopped because of lung malignancy. Furthermore, the DAS28\u2010ESR remained comparable before and after the switch, with a mean (SD) of 2.34 (\u00b11.02) and 2.31 (\u00b11.11) respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In our population, 87% of patients continued Remsima during the follow\u2010up period of approximately 2 years. Three patients restarted Remicade, while retaining stable DAS28\u2010ESR.<\/jats:p><\/jats:sec>","DOI":"10.1111\/1756-185x.13512","type":"journal-article","created":{"date-parts":[[2019,2,15]],"date-time":"2019-02-15T06:19:33Z","timestamp":1550211573000},"page":"869-873","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Efficacious transition from reference infliximab to biosimilar infliximab in clinical practice"],"prefix":"10.1111","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8245-9725","authenticated-orcid":false,"given":"Zohra","family":"Layegh","sequence":"first","affiliation":[{"name":"Amsterdam Rheumatology and Immunology Center Reade, Rheumatology Amsterdam The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jill","family":"Ruwaard","sequence":"additional","affiliation":[{"name":"Amsterdam Rheumatology and Immunology Center Reade, Rheumatology Amsterdam The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renske C. F.","family":"Hebing","sequence":"additional","affiliation":[{"name":"Amsterdam Rheumatology and Immunology Center Reade, Rheumatology Amsterdam The Netherlands"},{"name":"Reade, Rheumatology, Pharmacy Amsterdam The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Merel J.","family":"l\u2019 Ami","sequence":"additional","affiliation":[{"name":"Amsterdam Rheumatology and Immunology Center Reade, Rheumatology Amsterdam The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wilfred","family":"van der Weele","sequence":"additional","affiliation":[{"name":"Amsterdam Rheumatology and Immunology Center Reade, Rheumatology Amsterdam The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mike T.","family":"Nurmohamed","sequence":"additional","affiliation":[{"name":"Amsterdam Rheumatology and Immunology Center Reade, Rheumatology Amsterdam The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlotte","family":"Krieckaert","sequence":"additional","affiliation":[{"name":"Amsterdam Rheumatology and Immunology Center Reade, Rheumatology Amsterdam The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gertjan","family":"Wolbink","sequence":"additional","affiliation":[{"name":"Amsterdam Rheumatology and Immunology Center Reade, Rheumatology Amsterdam The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2019,2,14]]},"reference":[{"key":"e_1_2_7_2_1","unstructured":"European Commission.What you need to know about biosimilar medicinal products.http:\/\/www.medicinesforeurope.com\/wpcontent\/uploads\/2016\/03\/biosimilars_report_en.pdf. Accessed February 12 2018."},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)05246-0"},{"key":"e_1_2_7_4_1","unstructured":"EMA.Remsima infliximab.http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/002576\/human_med_001682.jsp&mxml:id=WC0b01ac058001d124. Accessed March 19 2018."},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30068-5"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-016-0981-6"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-016-0930-4"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.40324"},{"key":"e_1_2_7_9_1","unstructured":"NVZA.Toolbox biosimilars.http:\/\/nvza.nl\/wp-content\/uploads\/2017\/04\/NVZA-Toolbox-biosimilars_7-april-2017.pdf. Accessed April 20 2018."},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.2015.1103733"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210742"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200011303432202"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.10697"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22788"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3001244"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1136\/postgradmedj-2012-131730"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.2197-10.2010"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2012.115"},{"key":"e_1_2_7_19_1","first-page":"78","article-title":"Placebo and nocebo responses in randomised controlled trials of drugs applying for approval for fibromyalgia syndrome treatment: systematic review and meta\u2010analysis","volume":"30","author":"Hauser W","year":"2012","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_7_20_1","unstructured":"US Food & Drug Administration.Guidance for industry. Biosimilars: questions and answers regarding implementation of the Biologics Price Competition and Innovation Act of 2009.2015.http:\/\/www.fda.gov\/downloads\/drugs\/guidancecomplianceregulatoryinformation\/guidances\/ucm444661.Pdf. Accessed October 31 2018."},{"key":"e_1_2_7_21_1","unstructured":"Committee for Medicinal Products for Human Use.Guideline on similar biological medicinal products containing biotechnology\u2010derived proteins as active substance: non\u2010clinical and clinical issues.2006.http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/09\/WC500003920.pdf. Accessed January 15 2019."}],"container-title":["International Journal of Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2F1756-185X.13512","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1756-185X.13512","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/1756-185X.13512","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1756-185X.13512","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,10]],"date-time":"2023-09-10T23:28:07Z","timestamp":1694388487000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1756-185X.13512"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,14]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["10.1111\/1756-185X.13512"],"URL":"https:\/\/doi.org\/10.1111\/1756-185x.13512","archive":["Portico"],"relation":{},"ISSN":["1756-1841","1756-185X"],"issn-type":[{"type":"print","value":"1756-1841"},{"type":"electronic","value":"1756-185X"}],"subject":[],"published":{"date-parts":[[2019,2,14]]},"assertion":[{"value":"2018-06-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-01-22","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-02-14","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}